Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
MWN-AI** Summary
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focused on innovative precision medicines, is set to present at the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12–15, 2026, in San Francisco, California. Helen Sabzevari, PhD, the company’s President and CEO, will deliver a presentation on January 15, 2026, at 7:30 AM PT. Additionally, she will engage in a fireside chat hosted by Eversana, Precigen's commercialization partner, on January 12, 2026, at 10:30 AM PT, during the Biotech Showcase, which occurs alongside the conference.
Precigen is committed to developing innovative therapies addressing significant unmet medical needs, primarily in the areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company's pipeline includes promising candidates like PAPZIMEOS™ (zopapogene imadenovec-drba), aimed at treating recurrent respiratory papillomatosis (RRP) in adults. Precigen’s approach seeks to bridge scientific breakthroughs with successful commercialization strategies.
In their press release, Precigen emphasizes the importance of transparency regarding forward-looking statements, highlighting various factors that could affect the company's future performance, including the success of PAPZIMEOS in gaining foreign regulatory approvals and the timing and results of clinical trials. The company warns that actual outcomes may vary significantly from expectations due to these uncertainties.
Investors and stakeholders can find further information regarding these upcoming presentations on Precigen's website under the Events & Presentations section. For media and investor inquiries, Precigen provides contact details for Steven M. Harasym and Donelle M. Gregory, ensuring open lines of communication as the company advances its mission in precision medicine.
MWN-AI** Analysis
As Precigen, Inc. (Nasdaq: PGEN) prepares for its presentation at the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 15, 2026, investors should approach this opportunity with both enthusiasm and caution. This conference is one of the most highly anticipated events in the healthcare sector, granting companies like Precigen a platform to showcase their innovations and strategic directions.
Precigen specializes in developing precision medicines for difficult-to-treat diseases, which positions it uniquely in the biopharmaceutical landscape. During her presentation, CEO Dr. Helen Sabzevari is poised to discuss the company's latest advancements, particularly regarding its leading therapy, PAPZIMEOS™ (zopapogene imadenovec-drba), aimed at treating recurrent respiratory papillomatosis (RRP). The successful commercial rollout and possible regulatory approvals for this treatment could significantly impact market perceptions and stock valuation.
Investors should closely monitor the tone and content of Dr. Sabzevari's discussions, particularly around clinical trial timelines, the safety and efficacy data of current candidates, and the overall commercialization strategy. Given the competitive nature of the biotech sector, any positive updates may lead to a bullish response from the market. Conversely, if the presentation highlights delays or setbacks, it could result in a negative reaction.
Additionally, participation in the fireside chat with Eversana offers a further dimension of collaboration that could enhance commercialization prospects. However, it’s important to be mindful of the inherent risks outlined in their forward-looking statements, particularly surrounding regulatory approvals and clinical trial outcomes.
In summary, while the upcoming conference provides a potential catalyst for Precigen’s stock performance, prudent investors should analyze the information disclosed, assess the risks, and remain aware of market volatility tied to biotech developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
GERMANTOWN, Md., Jan. 5, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, today announced that Helen Sabzevari, PhD, President and Chief Executive Officer of Precigen, will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026 in San Francisco, California. Dr. Sabzevari's company presentation is scheduled for Thursday, January 15, 2026 at 7:30 AM PT.
In addition, Dr. Sabzevari will participate in a fireside chat hosted by the Company's commercialization operations partner, Eversana, on Monday, January 12, 2026 at 10:30 AM PT at the Biotech Showcase, which runs January 12–14, 2026 in San Francisco.
Participants may view details for these events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company's other product candidates, the timing of clinical trials and their results, the Company's ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.
Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
SOURCE Precigen, Inc.
FAQ**
How does Precigen Inc. PGEN plan to leverage its pipeline in immuno-oncology and autoimmune disorders to address unmet patient needs in these areas during the upcoming 44th Annual J.P. Morgan Healthcare Conference?
Can you provide an update on the progress of PAPZIMEOS for treating recurrent respiratory papillomatosis (RRP) and any anticipated milestones for Precigen Inc. PGEN in the near future?
What strategies does Precigen Inc. PGEN have in place to obtain necessary regulatory approvals for PAPZIMEOS, and how are you navigating the current regulatory landscape?
How does Precigen Inc. PGEN plan to enhance its commercialization efforts in partnership with Eversana, especially in light of your upcoming fireside chat at the Biotech Showcase?
**MWN-AI FAQ is based on asking OpenAI questions about Precigen Inc. (NASDAQ: PGEN).
NASDAQ: PGEN
PGEN Trading
3.01% G/L:
$3.559 Last:
976,747 Volume:
$3.56 Open:
